IP Library Granted Patent US 12,201,836
Granted Patent B2
US 12,201,836 · App. 17/342,186 · Granted Jan 21, 2025

Techniques for neuromodulation

Inventors: Christopher Michael Puleo (Niskayuna, NY); Jeffrey Michael Ashe (Gloversville, NY); Victoria Eugenia Cotero (Watervliet, NY); Michael Ernest Marino (Niskayuna, NY)
Assignee: GENERAL ELECTRIC COMPANY
A61N1/36071A61N1/3606A61N1/36121A61N1/36153A61N1/36171A61N2/006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,836
App. No.
17/342,186
Filed
Jun 8, 2021
Granted
Jan 21, 2025
Kind
B2
Art Unit
3792
USPC
607/2
Abstract

The subject matter of the present disclosure generally relates to techniques for neuromodulation of lymphatic tissue that include applying one or more energy pulses to a neuron of a subject, e.g., via an electrode positioned to deliver sufficient energy to the neuron, to modulate immune function. For example, an adaptive immune reflex of a subject may be modulated via neuromodulation.

Claims (24)

1. A method of neuromodulation, comprising:

applying one or more energy pulses to a neuron of a subject to deliver sufficient energy to the neuron to neurally modulate a lymphatic tissue in response to applying the one or more energy pulses;

acquiring image data of the lymphatic tissue using an ultrasound imaging probe; and

changing modulation parameters of the one or more energy pulses based on the image data.

2. The method of claim 1 , wherein the lymphatic tissue is a lymph node.

3. The method of claim 1 , wherein the neuron is a parasympathetic or sympathetic neuron innervating a primary, secondary, or tertiary lymphatic tissue structure or communicating tissue.

4. The method of claim 1 , wherein the subject has a diagnosis of an autoimmune disorder.

5. The method of claim 1 , wherein acquiring the image data comprising acquiring baseline image data and post-modulation image data.

6. The method of claim 5 , wherein the post-modulation image data is acquired within 30 minutes of applying the one or more energy pulses.

7. The method of claim 1 , wherein changing the modulation parameters comprises decreasing or stepping back energy levels of the one or more energy pulses.

8. The method of claim 1 , wherein the image data is indicative of an increase in size of the lymphatic tissue above a threshold, wherein the increase in size is indicative of successful modulation.

9. The method of claim 1 , wherein the increase in size is an increase in volume of the lymphatic tissue.

10. The method of claim 1 , wherein the image data is indicative of a lack of change in size of the lymphatic tissue relative to a threshold, and wherein a controller is configured to increase the modulation parameters based on the lack of change in size.

11. The method of claim 1 , wherein applying the one or more energy pulses causes the lymphatic tissue to increase in size, wherein the lymphatic tissue is a lymph node, and wherein the increase in size of the lymph node is associated with a decrease in lymphocyte egress from the lymph node.

12. A system for neuromodulation of lymphatic tissue, comprising:

an energy application device configured to apply one or more energy pulses to a neuron of a subject to deliver sufficient energy to the neuron to neurally modulate a lymphatic tissue in response to applying the one or more energy pulses;

a noninvasive ultrasound imaging probe configured to acquire image data of the lymphatic tissue before and after neurally modulating the lymphatic tissue; and

a controller configured to:

cause the energy application device to generate the one or more energy pulses according to modulation parameters;

identify a change in size of the lymphatic tissue caused by applying the one or more energy pulses based on the image data; and

change the modulation parameters based on the identified change in size of the lymphatic tissue.

13. The system of claim 12 , wherein the lymphatic tissue is a lymph node.

14. The system of claim 12 , wherein the subject has a diagnosis of an autoimmune disorder.

15. The system of claim 12 , wherein the change in size is relative to a baseline size determined from the image data acquired before neurally modulating the lymphatic tissue.